All Articles

CIMG Inc. just won a "Most Investable" award, but a look under the hood reveals a company grappling with cash burn and a risky crypto strategy.

U.S. healthcare tech faces a talent crisis. The solution may lie in an unexpected place: a booming freelance market in Poland and Eastern Europe.

A surge in demand for an all-in-one dog walking kit reveals a deeper trend: how brands are using strategic design to win in the booming pet market.

A pivotal FDA meeting may have put Atossa Therapeutics' novel breast cancer drug, (Z)-endoxifen, on an accelerated path, a strategic win for investors.

For the seventh year, Greif tops a key responsibility list. We explore how the packaging giant turned ESG consistency into a powerful business advantage.

Camping World's latest dividend signals stability, but a deeper look reveals a complex strategy to navigate RV market headwinds and capitalize on new trends.

Volatus Aerospace appoints a top retired general, a strategic play to capture a share of Canada's multi-billion-dollar defense and NORAD modernization.

Beyond 200,000 houses, Meritage Homes' focus on energy efficiency and affordability is laying the foundational infrastructure for our connected future.

Reeling from a trial failure, Neuphoria Therapeutics battles an activist's lowball bid while its board scrambles to unlock hidden value in a high-stakes review.

A novel drug aims to replace toxic chemo and conquer aggressive breast cancer. Can Intensity Therapeutics' direct tumor injection shift the treatment paradigm?

An AWS award for Smarsh signals a seismic shift in financial compliance. Discover how AI and the cloud are rewriting the rules for risk management.

An Israeli biotech's manufacturing milestone isn't just a production win; it's a strategic move to commercialize its nasal shield technology.

Cambridge biotech Atavistik Bio reveals a novel allosteric inhibitor targeting a key MPN mutation, promising disease modification without current side effects.

A new survey finds social service workers optimistic about automation, but can technology truly fix a system plagued by staff shortages and policy hurdles?

As the EU rolls out its Digital Product Passport, the BSV Association is positioning its scalable blockchain as the key to unlocking supply chain trust.

A $3M deal values Eye-Net's V2X tech at $55M, but the complex warrant structure tells a deeper story about Foresight's strategic play in road safety.

Fresh off a massive IPO, MapLight Therapeutics is racing toward pivotal data in schizophrenia and Alzheimer's. Can it defy the odds in biotech's riskiest field?

Beyond its third 'Global Bank of the Year' award, DBS is pioneering a future where AI protects customers and sustainability drives finance. What does this mean for us?

With nickel prices low, FPX Nickel is doubling down on its own stock. Is this a savvy capital move or a signal of a unique, undervalued asset?

With a BMO veteran on its board and a 1.5M oz gold project, junior miner Q-Gold signals a strategic shift from exploration to serious development.